185055-67-8
基本信息
FERROQUINE
Ferrochloroquine
7-Chloro-4-(((2-((dimethylamino)methyl)ferrocenyl)methyl)amino)quinoline
報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
2024/11/08 | HY-19364 | 二茂鐵氯喹 Ferroquine | 185055-67-8 | 2mg | 650元 |
2024/11/08 | HY-19364 | 二茂鐵氯喹 Ferroquine | 185055-67-8 | 5mg | 1360元 |
2024/11/08 | HY-19364 | 二茂鐵氯喹 Ferroquine | 185055-67-8 | 10mM * 1mLin DMSO | 1496元 |
常見問題列表
antimalarial
Ferroquine shows cytotoxicity against non-cancerous MRC-5 and HeLa cancer cells with IC
50
values of 24.4 μM and 16.8 μM, respectively.
24?hours post-incubation all newly transformed schistosomula (NTS) exposed to 33.3?μM Ferroquine shows strongly reduced viabilities.
Treatment of mice with 200 and 800?mg/kg Ferroquine, shows low total worm burden reductions of 19.4% and 35.6%. One of the mice treated with 800?mg/kg Ferroquine died within 24?hours post-treatment. No activity is observed treating mice with RQ at 200?mg/kg. Finally, a total worm burden reduction of 17.3% is observed following treatment with FQ-OH. Hence, modification of Chloroquine (CQ) by a ferrocenyl or ruthenocenyl fragment does not increase the antischistosomal properties of CQ. For comparison, at 200?mg/kg mefloquine (MQ) achieves a much higher worm burden reduction of 72.3% in S. mansoni -infected mice. A higher effect against female adult S. mansoni is also observed in MQ treated mice pointing to a sex-specific interference of these drugs with the target. Furthermore, in one of the FQ-OH treated mice many dead worms are recovered and a hepatic shift (i.e. worms migrating to the liver) observed. Hence, Ferroquine and FQ-OH show weak antischistosomal activity in vivo.